Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
397.48
-0.22 (-0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
February 01, 2024
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.
Via
InvestorPlace
Biotech And Medtech Portfolio Notes On A Fed Day
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Buy Alert: 3 Stocks Sitting in the Sweet Spot
January 31, 2024
They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting.
Via
InvestorPlace
Key Takeaways From Vertex Pharmaceuticals Analyst Ratings
January 31, 2024
Via
Benzinga
Why Vertex Pharmaceuticals Stock Topped the Market Today
January 30, 2024
The company reported that it met its primary endpoint in a study for its non-opioid pain drug.
Via
The Motley Fool
Here's My Top Growth Stock to Buy Right Now
January 27, 2024
There doesn't appear to be a weak link with this great stock.
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
January 25, 2024
As the adage goes, winners keep winning.
Via
The Motley Fool
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
January 23, 2024
Via
Benzinga
Why Is Vertex Pharmaceuticals Stock Sliding Today?
January 30, 2024
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.
Via
Benzinga
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst
January 30, 2024
The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal.
Via
Investor's Business Daily
Is CRISPR Therapeutics a Buy in the New Bull Market?
January 30, 2024
CRISPR Therapeutics is a specialist in the hot technology of gene editing.
Via
The Motley Fool
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
January 29, 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
It's always tough to be compared to a giant.
Via
The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
January 24, 2024
The company could maintain the momentum it gained last year.
Via
The Motley Fool
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
January 24, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today
January 24, 2024
These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
Via
Benzinga
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
January 23, 2024
Despite A bump in the road, the biotech's future looks sunny.
Via
The Motley Fool
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
January 22, 2024
These stocks seem likely to keep up their winning ways.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
January 22, 2024
Via
Benzinga
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
January 22, 2024
Has investing in Vertex been a better option than just putting your money in the S&P 500?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
January 22, 2024
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.
Via
Investor's Business Daily
Topics
ETFs
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
January 20, 2024
These big winners of 2023 could keep their momentum going in the new year.
Via
The Motley Fool
These 2 Phenomenal Growth Stocks Can Make You Richer in 2024
January 20, 2024
One market-beating stock and one beaten-down stock look like tempting buys for very different reasons.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.